TARS Tarsus Pharmaceuticals, Inc.

NASDAQ
$73.01

Tarsus Pharmaceuticals, Inc. (TARS) is expected to report earnings on February 2, 2027, after the market close. The consensus earnings estimate is a loss of $0.39 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.4% since its last earnings release on November 3, 2026.

Tarsus Pharmaceuticals, Inc. Beat Consensus Estimates
Tuesday, November 3, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 2
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.39)
Rev est $208.54M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $72.69

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.